GlassScriptPhysician profile
Daniel Wohlgelernter
NPI 1003836651
$871.24
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $120 · 2021: $59.92 · 2022: $19.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $189.01 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.40 | 2019-2021 | |
| Gilead Sciences, INC. | $121.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.38 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.43 | 2019 | |
| Abbott Laboratories | $38.98 | 2019-2020 | |
| Biotronik INC. | $34.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.37 | 2019 | |
| Amgen INC. | $29.89 | 2019 | |
| Pfizer INC. | $29.47 | 2021 | |
| Cathworks, INC. | $29.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.80 | 2019 | |
| Merck Sharp & Dohme LLC | $19.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wohlgelernter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.